3 companies with the world at their feet

Investors can look to profit from these health care companies' growth.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Globalisation has changed the world, and in the health care sector it's giving some companies opportunities others can only dream of. Strong competitive advantages help make these three companies look like an investor's dream.

With just 6% of sales coming from Australia, Ansell (ASX: ANN) is a global healthcare leader. The condom and medical device manufacturer grew net profit to $136.8 million in financial year 2013, up 5.2% on the prior year.

Emerging markets now represent 27% of sales, which were up 34% in the Middle East and Africa and 22% in Latin America and the Caribbean. Acquisitions were recently completed in Europe, North and Latin America. Markets like Brazil, Mexico, India and China offer further growth potential. With a strong product portfolio and growing global presence, the future looks bright.

A second global wonder from down under is CSL (ASX: CSL). It manufactures life-saving medicines as well as influenza and travel vaccines. The company recently announced a net profit of US$1.22 billion for financial year 2013, up 19% on last year. Its core business is the sale and development of blood plasma products and it's benefitting from growing demand in countries like China and Brazil. Already a global giant, 2014's forecast profit growth is approximately 10% and with over 88% of the group's sales revenues generated outside Australia, it looks immune to a predicted slowdown in the domestic economy.

The third global phenomenon is sleep treatment device manufacturer ResMed (ASX: RMD). Medical professionals now increasingly recognise daytime sleepiness or fatigue in people as a consequence of sleep apnea, a breathing disorder that impacts a patient's sleep quality. ResMed's products to treat such disorders are sold in approximately 100 countries and there seems no limit to the company's ambitions.

ResMed's annual report cites a scientific study that estimates 26% of adults aged 30-70 have some form of treatable sleep apnea. In its main market, the United States, that's 46 million people alone. Unsurprisingly, the company keeps growing, sales outside the Americas accounted for 44% of revenues in financial year 2013 and net profit jumped an impressive 21%.

An overall trend towards consolidation in the healthcare industry means companies with economy of scale advantages should deliver for investors. Best-in-class reputations and products cement a tempting trio's investment case.

Foolish takeaway

Quality companies don't come cheap and all three sport demanding price-to-earnings ratios, with prices approaching 52-week highs. This should not put investors off though — stock prices remain forward-looking indicators and 52-week highs can become 52-week lows on long-term horizons.

Interested in our #1 dividend-paying stock? Discover The Motley Fool's favourite income idea for 2013-2014 in our brand-new, FREE research report, including a full investment analysis! Simply click here for your FREE copy of "The Motley Fool's Top Dividend Stock for 2013-2014."

More reading


Motley Fool contributor Tom Richardson owns shares in ResMed.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »